Jun. 29 at 4:37 PM
$FBRX | derisked autoimmune platform, celiac Ph2 dead ahead
FB102 is an IV anti-CD122 mAb — it blocks the IL-2/IL-15 receptor beta-subunit, shutting down the NK +
CD8 T-cells that drive the autoimmune attack. One molecule, multiple indications. A real “pipeline-in-a-product.”
ALREADY DERISKED IN PH1B — celiac data HIT:
• Stat-sig on the histologic VCIEL endpoint (p=0.0099)
• 73% relative improvement in villus:crypt ratio
• IEL density benefit (p=0.0035)
• 42% drop in gluten-induced GI symptoms
• ZERO dropouts, clean Grade 1 safety
That’s proof of mechanism — not a hope-and-a-prayer setup.
WHY PH2 IS BUILT TO WIN (FB102-301):
The protocol is engineered to WIDEN the separation vs placebo:
• ~100 pts, up to 30 US sites, 80% on drug
• TWO doses tested (vs a single dose in Ph1b)
• 8 infusions — 5 weekly + 3 biweekly (vs just 4 doses in Ph1b) = more exposure
• ~54-day gluten challenge (vs 16 days in Ph1b) — longer challenge = more placebo-arm damage =
bigger gap for FB102 to protect
• FDA FAST TRACK in celiac — a market with LITERALLY NO approved drug. Mechanism is independent of gluten exposure, so it works where gut-restricted / enzyme approaches don’t.
CATALYST STACK (loaded year):
• Celiac Ph2 topline — 2026, mgmt says readouts “coming shortly” — THE event
• Vitiligo Ph1b — 1H 2026, imminent
• Alopecia areata Ph1b — 2026
Shared CD122 mechanism = each positive read cross-validates the others. One win can re-rate the whole platform.
FUNDED THROUGH IT:
~
$162M net raised in April → ~
$205M cash, runway clear past the catalyst cluster. Multi-billion-$ combined TAM across celiac + vitiligo + alopecia, with T1D optionality behind it.
Long FBRX into the celiac read. The Ph1b told us the biology is real — Ph2 takes that signal, adds more doses + a longer challenge, and gives it room to express.
Not financial advice. DYOR.
